Redhill Biopharma Stock News

RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations  Unique Mode of ActionOpaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of concern--Regulatory updateOpaganib global Phase 2/3 data packages submitted to Europ...

RedHill Biopharma Ltd (NASDAQ:RDHL) has said that because its opaganib treatment's proposed mechanism of action is not impacted by spike protein mutations, the drug is expected to be unaffected by mut

Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong ratio

(PR-inside.com) Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of concern Regulatory update Opaganib global Phase 2/3 data packages submitted to European EMA, with initial feedback expected by end of year, to the U.S. FDA with initial feedback expected in January, and to the UK MHRA, with other countries lined up A number of pending grant applications in the U.S. and abroad with both government bodies ..

Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of concern Regulatory update Opaganib global Phase 2/3 data packages submitted to European EMA, with initial feedback expected by end of year, to the U.S. FDA with initial feedback expected in January, and to the UK MHRA, with other countries lined up A number of pending grant applications in the U.S. and abroad with both government bodies and non-government entities Opaganib designed for underserved hospitalized patient population with advanced disease; Opaganib treatment initiated a median of 11 days from symptom onset in the Phase 2/3 global study, compared to the limited 3-5-day from symptom onset scope of the Pfizer & Merck pills RHB-107, RedHill''s other oral COVID-19 drug candidate, expected to deliver top-line data in Q1/2022 from Part A of its Phase 2/3 study in non-hospitalized patients in the U.S. and South Africa ; RHB-107 also not expected to be impacted by spike protein mutations TEL AVIV, Israel and RALEIGH, N.C. , Dec. 6, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that because opaganib''s [1] proposed mechanism of action is not impacted by spike protein mutations, opaganib is expected to be unaffected by mutations associated with Omicron and other known variants of concern.

The stock price of RedHill Biopharma Ltd (NASDAQ: RDHL) increased by over 9% pre-market today. This is why it happened.

RedHill Biopharma (NASDAQ:RDHL) had its price target reduced by BTIG Research from $16.00 to $10.00 in a research report report published on Wednesday morning, The Fly reports. BTIG Research currently has a buy rating on the biotechnology companys stock. A number of other research analysts also recently commented on RDHL. Cantor Fitzgerald began coverage on []

The stock price of RedHill Biopharma Ltd (NASDAQ: RDHL) increased by over 6% during intraday trading. This is why it happened.

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced the publication of a new study of Talicia to treat H. pylori infection.

RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMIHigh Body Mass Index and obesity are known risk factors for H. Pylori eradication treat

RedHill Biopharma (NASDAQ:RDHL) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.48) by ($0.02), Fidelity Earnings reports. RedHill Biopharma had a negative return on equity of 303.29% and a negative net margin of 112.40%. During the same quarter in []

RedHill Biopharma''s Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of AmericansMovantik® approved for inclusion as preferred and unrestric

RedHill Biopharma's (RDHL) CEO Dror Ben-Asher on Q3 2021 Earnings Call Transcript